CD22 and lymphoma: Given the heterogeneity of tumor cells, the development of CAR-Exosomes targeting multiple targets should also be explored, mirroring the success of dual-target CAR-T cell therapies (e.g., CD19/CD22) in refractory lymphomas (88).